Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-BN-RSV
- Development stage
- Phase 3
- Lead developer
- Bavarian Nordic
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
MVA-BN-RSV is a viral vector vaccine candidate developed by Bavarian Nordic for the prevention of respiratory syncytial virus (RSV) infection, specifically targeting older adults (≥60 years). The vaccine utilizes the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) platform, a non-replicating viral vector, to deliver five RSV antigens: the surface glycoproteins (F and G) from both RSV subtypes A and B, and three internal proteins (N, M2-1, and P). This multi-antigen approach was designed to elicit a broad immune response, including both neutralizing antibodies and robust T-cell activation. Despite showing promise in Phase 2 challenge studies and immunogenicity trials, the pivotal Phase 3 VANIR trial failed to meet its primary endpoint of preventing RSV-related lower respiratory tract disease (LRTD) in July 2023. Consequently, Bavarian Nordic discontinued the program and terminated its development partnership with Nuance Pharma.
- Brand names
- MVA-BN-RSV
- Other names
- recombinant MVA-BN-RSV vaccineMVA-BN RSV
02
Targets
RSV F (Respiratory syncytial virus fusion protein)RSV G (Respiratory syncytial virus attachment glycoprotein)RSV N (Respiratory syncytial virus nucleoprotein)M2-1 (Respiratory syncytial virus transcription antitermination factor M2-1)Major surface glycoprotein G (subtype A)
Beyond the preview
Go deeper on MVA-BN-RSV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-BN-RSV.